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Edited by Varda RotterAbstract Nucleotide excision repair (NER) deals with bulky
DNA damages. However, the regulation of this process is still
unclear. Here, we show that both cell resistance to genotoxic
agents that generate DNA lesions corrected by NER and in vitro
NER activity are correlated with atypical protein kinase C
(PKC) f expression levels. Moreover, repair intermediates are
produced and eliminated more rapidly in UV-irradiated PKCf-
overexpressing cells. The expression levels of XPC and hHR23B,
two NER proteins, are correlated with PKCf expression.
Altogether, these results strongly suggest that PKCf could act
as a modulator of NER activity by regulating the expression of
XPC/hHR23B heterodimer.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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hHR23B1. Introduction
Cellular DNA is exposed to various genotoxic stresses such
as reactive oxygen species, radiations, or carcinogens. De-
pending on the levels of DNA damages, cells switch either to
cell cycle progression arrest in order to allow time for DNA
repair and further resume cell cycle, or to apoptosis. However,
cells can also tolerate some unrepaired DNA damage poten-
tially leading to mutagenesis and carcinogenesis.
Several mechanisms are available to repair DNA damage
(for review, see [1]). Nucleotide excision repair (NER) is
mainly implicated in the removal of DNA lesions such as helix-
altering or bulky adducts on DNA. NER is a multistep process
involving more than 30 proteins [2]. Following lesion recog-
nition and dual incision 30 and 50 to damage, 27–29 nucleotides
are excised. DNA polymerase ﬁlls in the gap before ligationq Supplementary data associated with this article can be found, in the
online version, at doi: 10.1016/j.febslet.2004.08.024.
* Corresponding author. Fax: +33-562-744-558.
E-mail address: dominique.lautier@toulouse.inserm.fr (D. Lautier).
Abbreviations: AAS, atomic absorption spectrophotometry; MTT, 3-
(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide; NER, nu-
cleotide excision repair; PKC, protein kinase C; XP, xeroderma
pigmentosum
0014-5793/$22.00  2004 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2004.08.024[1,3]. Xeroderma pigmentosum (XP) is a clinical syndrome
resulting from NER defects, characterized by hypersensitivity
to UV light and very high incidence of skin tumors.
The protein kinase C (PKC) family comprises several pro-
teins that regulate major cell functions such as proliferation,
diﬀerentiation, motility, and apoptosis. Three classes of PKC
have been deﬁned on the basis of their primary structure and
biochemical properties: conventional PKC isotypes (a, b and
c), novel PKCs (d, e, g, and h), and atypical PKCs (the closely
related f and k=i isoforms) [4]. Several proteins involved in
genome integrity are regulated by PKC, including DNA-de-
pendent protein kinase [5], hMutsa [6,7], O(6)-methylguanine–
DNA methyltransferase [8], and topoisomerase II [9]. All these
observations suggest a pivotal role for PKC in the coordina-
tion of the diﬀerent DNA repair mechanisms. PKCf has re-
cently emerged as a critical component of survival pathways
activated by receptor and non-receptor tyrosine kinases, and
oncogenes [10]. In this study, we investigated whether PKCf
expression could also play a role in cell resistance to genotoxic
agents and in maintenance of genetic integrity by modulating
DNA repair mechanisms.2. Materials and methods
2.1. Cell lines and chemicals
U937 and HeLa cell lines were obtained from the ATCC (Rockville,
MD, USA). PKCf-transfected U937 cells were a gift from Dr. K. Ways
(Greenville, NC, USA). Brieﬂy, stable co-transfection of U937 cells was
done with pMAMneo (Clontech) and either PKCf plasmid (U937-fJ
and U937-fB clones) or vector without PKCf insert (U937-neo) by
electroporation [11]. U937 cells were grown in RPMI 1640 with 10%
fetal calf serum, 2 mM glutamine, streptomycin and penicillin. PKCf
expression and activity were increased by 4–5- and 3-fold, respectively,
in U937-fJ and U937-fB cells compared to U937-neo [11–13].
Stable PKCf gene suppression was done using GeneSuppressor kit
[14] according to the manufacturer’s recommendations (Imgenex,
Clinisciences Montrouge, France). Brieﬂy, human PKCf oligonucleo-
tide inserts were designed: PKCf forward 50TCGAGATCTTCAT-
CACCAGCGTGGAGAGTACTGTCCACGCTGGTGATGAAGA-
TTTTTT30; PKCf reverse: 50CTGAAAAAATCTTCATCACCA-
GCGTGGACAGTACTCTCCACGCTGGTGATGAAGATC 30 [14].
After primer annealing, inserts were cloned in the pSuppressor plasmid
containing Neomycin resistance gene. Following stable transfection of
HeLacells byLipofectamine 2000 (Invitrogen,CergyPontoise,France)
with siRNA PKCf plasmid, two HeLa cell clones, HeLa Si5 and HeLa
Si11, displaying a reduction by 50% and 60%, respectively, in PKCf gene
expression, were used.ation of European Biochemical Societies.
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Fig. 1. Eﬀect of PKCf on cell sensitivity, (a) Clonogenic assay of U937-
neo (r), U937-fJ () and U937-fB (n) cells following UV-C-irradi-
ation. (b) and (c) Cell viability measured by MTT assays performed
following cell treatment with cisplatin (b) or melphalan (c). The results
are means S.D. of three separate experiments.
122 T. Louat et al. / FEBS Letters 574 (2004) 121–125Melphalan (Alkeran) was provided by Wellcome Laboratories
(Paris). Other reagents were obtained from Sigma (St Quentin-Falla-
vier, France).
2.2. Clonogenic and cytotoxicity assays
U937 cells were irradiated with UV-C light (254 nm) in PBS, re-
suspended in complete medium and seeded on 96-well plates (10 cells/
well). After 7 days, the colonies larger than 50 cells were counted and
the percentage of cell survival was determined. HeLa cells were plated
at 200 cells/35 mm dish and UV-C irradiated next day. One week later,
cells were ﬁxed and stained with Crystal violet and colony larger than
50 cells was counted.
For the 3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bro-
mide (MTT) assay, cells (3 105 cells=ml) were treated for 1 h with
cisplatin or melphalan at 37 C in complete medium. Cells were wa-
shed, then seeded on 96-well plates (30 000 cells/well) for 48 h at 37 C.
MTT solution was added for 1 h at 37 C. Following centrifugation,
the supernatants were removed prior to addition of DMSO (100 ll).
Optical density was measured at 590/620 nm and the percentages of
surviving treated versus untreated cells were calculated.
2.3. In vitro DNA repair reactions
Whole cell extracts were prepared as described previously [15]. The
2959 bp pBS (pBluescript KS+; Stratagene, Amsterdam, Netherlands)
and the related 3738 bp pHM14 plasmid were prepared by alkaline
lysis method from Escherichia coli JM109. pBS plasmid was irradiated
with UV light at 254 nm (300 J/m2). This dose produces about 10 UV
lesions per plasmid (pBS-UV).
The repair synthesis assay was performed as already described [16],
Brieﬂy, cell extract proteins (200 lg) were incubated at 30 C for 3 h
with a reaction mixture containing damaged pBS (300 ng), untreated
pHM14 closed circular plasmids (300 ng), [a32P] dCTP (800 Ci/mmol)
(2 lCi) (ICN, Orsay, France), and glutamic acid potassium salt (60
mM) [15]. Puriﬁed plasmid DNA was linearized with EcoRV and
electrophoresed on a 1% agarose gel containing 0.5 lg/ml ethidium
bromide. Gels were processed on a phosphorimager and the radioac-
tivity was quantiﬁed. Speciﬁc incorporation of [a32P] dCMP was ex-
pressed as radiolabeled incorporation in the damaged versus
undamaged plasmid, and was normalized to the same amount of DNA
as determined from the ﬂuorograph of the ethidium bromide stained
gels.
2.4. Alkaline comet assay
The alkaline comet assay was performed as previously described [17].
Brieﬂy, cells (1 105) were mixed with 0.5% low melting point agarose
(Invitrogen) (75 ll) and layered onto microscope slide. The slides were
sham- or UV-C- irradiated on ice at 15 or 40 J/m2, and incubated or
not in complete medium for 15 or 60 min. The slides were immersed at
4 C for 1 h in a cold lysis buﬀer. The slides were placed on a horizontal
electrophoresis unit ﬁlled with freshly prepared alkaline solution and
exposed to alkali for 20 min at RT. Electrophoresis was conducted for
25 min at 25 V, 300 mA. The slides were rinsed with Tris–base (0.4 M,
pH 7.5), stained with ethidium bromide, and observed at 40 mag-
niﬁcation with a LSM410 invert laser scan microscope Zeiss equipped
with excitation laser at 488 nm. Images of randomly selected cells (150
cells for each clone) were analyzed and tail DNA was determined with
kinetic analysis comet 4.0.2 software.
2.5. Measurement of platinum–DNA adducts
Exponentially growing cells were treated with 40 lM cisplatin for 1 h
at 37 C, washed and incubated with complete medium. Cells
(15 106) were harvested after treatment or after additional incuba-
tion in drug-free medium for 2, 5 or 23 h and incubated in lysis buﬀer
(0.3 M NaCl, 5 mM EDTA, 0.5% SDS, and 100 lg/ml proteinase K).
After extraction using standard procedure, DNA was digested with S1
nuclease. Covalent platinum (Pt)–DNA adducts were measured by
ﬂameless atomic absorption spectrophotometry (AAS) as already
described [18].
2.6. Western blot analysis
Whole cell extracts were prepared in Laemmli buﬀer, and proteins
were separated in 10% SDS–PAGE and transferred to nitrocellulose
membrane (Amersham Pharmacia Biotech, Saclay, France). Mem-
branes were incubated with polyclonal anti-XPB (Santa Cruz, CA), or
anti-XPC, or monoclonal anti-hHR23B (Transduction Laboratories),and anti-b-actin (Neomarkers, Fremont, CA) antibodies overnight at 4
C, then incubated with horseradish peroxidase-conjugated antibody
(Jackson Laboratories, West Grove, PA). Proteins were visualized
using the ECL system (Amersham Pharmacia Biotech).
2.7. Statistical analyses
Statistical analyses were performed using the Student’s t test,
P < 0:01 was considered statistically signiﬁcant.3. Results
3.1. PKCf enhances cell resistance to genotoxic stress
We ﬁrst investigated whether PKCf could inﬂuence the
sensitivity of U937 cells to UV-C, cisplatin, and melphalan.
Clonogenic assays show that PKCf-transfected clones exhibit
a 3-fold increase in resistance to UV-C compared to control
U937-neo cells (Fig. 1(a)). Moreover, PKCf overexpression
results in a 4- and 20-fold increase in resistance to cisplatin or
melphalan treatment, respectively, compared to control cells,
as measured by MTT assay (Fig. 1(b) and (c)).
Fig. 3. Eﬀect of PKCf on removal of DNA photodamage. U937-neo
and U937-fJ cells were irradiated with UV-C light (15 and 40 J/m2)
and DNA strand breaks were measured just after irradiation on ice, or
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In vitro NER activity measures the capacity of cell protein
extracts to repair UV-C irradiated plasmids [16]. We compared
the basal activity in whole cell extracts from control and
PKCf-overexpressing U937 cells. The basal repair activity
shows a 7-fold increase in U937-fJ compared to U937-neo cells
(Fig. 2). A 4-fold increase is observed in U937-fB cell extracts.
These results strongly suggest that basal NER activity could be
increased in PKCf-overexpressing U937 cells.
3.3. PKCf accelerates UV-C-induced DNA damage repair
NER involves endonuclease activity that generates repair-
induced strand breaks in damaged DNA. We determined the
rate of DNA repair after UV irradiation by alkaline comet
assay. The tail DNA reﬂects the appearance of repair-induced
strand breaks. In PKCf-transfected and control cell lines, tail
DNA increases with the dose of UV irradiation. However, tail
DNA is maximum at 15 and 60 min following UV-irradiation
in U937-fJ and U937-neo cells, respectively (Fig. 3). After 60
min, tail DNA is markedly decreased in U937-fJ cells but still
increased in U937-neo cells. These results suggest that UV
lesions are excised more rapidly and that repair process is
faster in U937-fJ than in control cells.
3.4. PKCf improves covalent Pt–DNA adduct elimination
To further investigate the inﬂuence of PKCf on DNA re-
pair, we measured the amount of covalent Pt–DNA adducts in
U937-fJ, U937-fB, and U937-neo cells treated with cisplatinFig. 2. In vitro NER activity in PKCf-overexpressing cells, (a) DNA
repair synthesis activity in U937-neo and U937-fJ cell extracts was
determined on UV-C damaged plasmids. (a) Ethidium bromide stained
gel (upper) and gel autoradiography (lower) are shown, (b) Quantiﬁ-
cation of NER activity was expressed as the ratio of radiolabeled
dCMP incorporation in the damaged versus undamaged plasmid. The
NER activity of the U937-neo cell extracts was arbitrary set at 1.
Results are means S.D. of three separate experiments performed with
three independent cell extracts.
after incubation at 37 C for 15 or 60 min following irradiation. A
representative experiment is shown (a–d). Cells were mock-irradiated
(a,c) or irradiated at 40 J/m2 (b,d) and analyzed 15 min after irradia-
tion. Complete results expressed as means of the tail DNA are shown
for U937-neo (e) and U937-fJ (f) cells.for 1 h treatment. At the end of treatment, the amount of Pt–
DNA adducts is similar (20 3.4 ng Pt/lg DNA) in the three
cell lines. This result suggests that PKCf does not interfere
with cisplatin uptake and eﬄux. Two hours after cisplatin re-Pt
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Fig. 4. Kinetics of covalent cisplatin–DNA adduct removal in U937-
neo (r), U937-fJ () and U937-fB (n) cells. DNA was extracted at
diﬀerent times after treatment with 40 lM cisplatin and platinum (Pt)
was quantiﬁed by AAS. Results are expressed as percentages of Pt–
DNA adduct remaining compared to the amount of Pt–DNA adducts
just after treatment. Each data is the meanS.D. obtained from three
independent experiments performed with three independent prepara-
tions of DNA.
Fig. 5. Eﬀect of PKCf siRNA on cell response to UV-C. (a) Clono-
genic assay of control HeLa (r), HeLa Si5 () and HeLa Si11 (n) cells
following cell irradiation. (b) In vitro NER activity in PKCf siRNA
cells. Photograph of ethidium bromide stained gel (upper) and gel
autoradiography (lower). DNA repair activity was quantiﬁed as in Fig.
2. The DNA repair activity of control HeLa cell extracts was arbitrary
set at 1.
Fig. 6. Expression of some NER components. Expression of XPB, XPC and h
fB (white) cells, and (c–d) HeLa (black), HeLa Si5 (grey) and HeLa Si11 (w
experiments and the quantiﬁcation is the meanS.D. of these experiments.
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U937-neo cells while only 10% of Pt–DNA adducts are de-
tected in U937-fJ or U937-fB cell DNA (Fig. 4). Twenty-three
hours after cisplatin removal, only 10% Pt–DNA adducts still
remain in U937-fJ or U937-fB cells, contrasting with more
than 30% in U937-neo cells. These results suggest that PKCf
enhances Pt–DNA adduct removal.
3.5. PKCf downregulation sensitizes cells to UV-C irradiation
and inhibits NER activity
We investigated the eﬀects of PKCf depletion on cell sur-
vival following UV irradiation and NER activity in HeLa cells.
Two stable siRNA-transfected HeLa clones, displaying lower
PKCf expression (Si5 and Si11), were signiﬁcantly sensitized to
UV-C compared to control HeLa cells (Fig. 5(a)). Moreover,
in vitro NER activity was signiﬁcantly decreased in HeLa Si5
cells (Fig. 5(b)). These results support a role for PKCf in the
control of NER activity.
3.6. PKCf expression levels correlate with some NER protein
expression
We hypothesized that PKCf could interfere with some steps
of NER process. We evaluated the expression levels of diﬀerent
NER proteins. Although no changes in PCNA, XPD, XPE
(data not shown) and XPB protein expression levels are de-
tected, a 10- and 5-fold increase in XPC and hHR23B protein
expression levels, respectively, is observed in PKCf-overex-
pressing cells compared to control cells (Fig. 6(a) and (b)).
Conversely, in PKCf siRNA-transfected cells, XPC and
hHR23B protein expression levels are decreased (Fig. 6(c) and
(d)). Interestingly, XPC and hHR23B mRNA levels are similar
in U937-fJ, U937-fB and in U937-neo cells, as revealed by
semi-quantitative RT-PCR (data not shown). These results
suggest that PKCf could interfere with XPC and hHR23B
expression at a post-transcriptional level.HR23B proteins in (a–b) U937-neo (black), U937-fJ (grey) and U937-
hite) cells. The Western blots are representatives of three independent
T. Louat et al. / FEBS Letters 574 (2004) 121–125 1254. Discussion
In this study, we provide evidence that PKCf expression can
aﬀect cell response to genotoxic agents. Overexpression of
PKCf markedly increases resistance to these agents. This re-
sistance could be related to increased basal NER activity, as
suggested by both in vitro NER activity measurements and
comet assays. Quantiﬁcation of Pt–DNA adducts and kinetic
studies of Pt–DNA adduct removal indicate that PKCf over-
expression does not protect cells by decreasing the number of
initial DNA lesions, but rather improves Pt–DNA adduct re-
moval. Therefore, our data strongly suggest that PKCf could
play an important role in the regulation of NER activity.
We found that PKCf overexpression correlates with in-
creased XPC/hHR23B protein expression, suggesting that
PKCf could improve the cell capacity to detect DNA damage.
The improvement of this step has been shown to increase
DNA repair eﬃciency [19]. Therefore, our study suggests that
the regulatory function of PKCf on NER activity could be
mediated by XPC/hHR23B overexpression. As transcriptional
regulation of XPC/hHR23B expression can be ruled out,
PKCf probably interferes at a post-transcriptional level. We
then investigated whether PKCf could interact with XPC and/
or hHR23B. Co-immunoprecipitation experiments failed to
show any interaction between these proteins (data not shown).
No modiﬁcation of the phosphorylation status of XPC and/or
hHR23B was observed (data not shown). No diﬀerences in the
stability of XPC and hHR23B were detected between control
and PKCf-overexpressing cells (data not shown).
Therefore, the mechanism by which PKCf modulates NER
expression is likely to result from XPC/hHR23B overexpres-
sion, but the mechanism by which PKCf modulates expression
of XPC/hHR23B proteins remains unclear.
Recently, the activation of ERK1/2 MAPK in response to
lead acetate was recently reported to increase NER activity as
well as cell resistance and anti-mutagenicity [20]. Whether the
eﬀects we observed in our cell lines are mediated by ERKl/2
MAPK, one of the targets of PKCf, remains to be
demonstrated.
It was generally believed that the protective function of
PKCf against genotoxic agents was mediated by its anti-ap-
optotic function [21–24]. Our study suggests that PKCf could
also aﬀect cell response to some genotoxic agents by enhancing
DNA repair. As PKCf could upregulate NER activity and
prevent genotoxicity, PKCf could act as an important con-
tributor to genome integrity.
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